---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-003048"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2023-02-16T23:59:59+00:00"
generated_at: "2026-06-19T09:17:08.204698+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx reports FY2022 net loss $707M, revenue $363M; guides 2023 rev $425-450M

## Summary
- FY2022 total revenue $363.3M (+3% YoY) from $351.4M in 2021.
- Net loss $707.4M ($10.12/sh) vs $454.0M ($6.70) in 2021, driven by higher R&D and acquired IP.
- Crysvita revenue $279.4M, Dojolvi $55.6M, Mepsevii $20.6M; cash $896.7M at year-end.
- 2023 guidance: total rev $425-450M; Crysvita $325-340M; Dojolvi $65-75M; net cash use <$400M.
- Q4 net loss $151.8M ($2.16/sh) vs $122.5M ($1.79) in Q4 2021.

## SEC filing metadata
- accession: 0000950170-23-003048
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2023-02-16T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000095017023003048/0000950170-23-003048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000095017023003048/rare-20230216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-003048
- JSON: https://secwatch.observer/filing/0000950170-23-003048.json
- Plain text: https://secwatch.observer/filing/0000950170-23-003048.txt

## Key facts
- Earnings Releases
  Ultragenyx Pharmaceutical Inc. reported Full year 2023 results: revenue Crysvita $325 million to $340 million; Dojolvi $65 million to $75 million. Guidance reaffirmed.
  - Period: Full year 2023
  - Revenue: Crysvita $325 million to $340 million; Dojolvi $65 million to $75 million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Total revenue in the range of $425 million to $450 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000095017023003048/0000950170-23-003048-index.htm
- Earnings Releases
  Ultragenyx Pharmaceutical Inc. reported Full year 2023 results: revenue Crysvita $325 million to $340 million; Dojolvi $65 million to $75 million. Guidance reaffirmed.
  - Period: Full year 2023
  - Revenue: Crysvita $325 million to $340 million; Dojolvi $65 million to $75 million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Crysvita revenue in the range of $325 million to $340 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000095017023003048/0000950170-23-003048-index.htm
- Earnings Releases
  Ultragenyx Pharmaceutical Inc. reported three months ended December 31, 2022 and year ended December 31, 2022 results: revenue $103.3 million for Q4 2022; $363.3 million for FY 2022, net income Net loss of $151.8 million for Q4 2022; Net loss of $707.4 million for FY 2022, EPS $(2.16) per share for Q4 2022; $(10.12) per share for FY 2022. Guidance reaffirmed.
  - Period: three months ended December 31, 2022 and year ended December 31, 2022
  - Revenue: $103.3 million for Q4 2022; $363.3 million for FY 2022
  - Net income: Net loss of $151.8 million for Q4 2022; Net loss of $707.4 million for FY 2022
  - EPS: $(2.16) per share for Q4 2022; $(10.12) per share for FY 2022
  - Guidance: reaffirmed
  - Result: reported results
  source text: Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
  evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000095017023003048/0000950170-23-003048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.